XLO

Xilio Therapeutics, Inc. (NASDAQ:XLO) is a clinical-stage biotechnology company founded in 2016 and headquartered in Waltham, Massachusetts. The company went public in October 2021 and focuses on developing innovative immunotherapies designed to enhance the immune system's ability to fight cancer. Xilio specializes in creating tumor-selective treatments that aim to overcome the limitations of traditional cancer immunotherapies by concentrating therapeutic activity specifically within the tumor microenvironment while minimizing systemic side effects.